# Research Letter

# From the Cochrane Library: Optical Coherence Tomography for Diagnosing Skin Cancer in Adults

Colin Burnette<sup>1</sup>, BSc; Torunn E Sivesind<sup>2</sup>, MD; Robert Dellavalle<sup>2,3</sup>, MD, PhD

<sup>1</sup>Nova Southeastern University College of Osteopathic Medicine, Davie, FL, United States

<sup>2</sup>Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States

<sup>3</sup>Rocky Mountain Reginal Veterans Affairs Medical Center, Aurora, CO, United States

#### **Corresponding Author:**

Robert Dellavalle, MD, PhD Rocky Mountain Reginal Veterans Affairs Medical Center 1700 N Wheeling St Rm E1-342 Aurora, CO, 80045 United States Phone: 1 720 857 5562 Fax: 1 720 723 787 Email: robert.dellavalle@cuanschutz.edu

#### (JMIR Dermatol 2023;6:e41355) doi: 10.2196/41355

#### **KEYWORDS**

systematic review; optical coherence tomography; tomography; diagnostic imaging; optical imaging; laser; skin lesions; diagnostic techniques; melanoma; basal cell carcinoma; cancer; skin cancer; clinical; cell; diagnose

Since the development of optical coherence tomography (OCT), technological improvements have made this diagnostic imaging tool adaptable to clinical settings [1]. OCT provides an alternative modality for assessing skin abnormalities. The standard procedure for the evaluation of suspicious skin lesions involves visual inspection, often with dermoscopy, which may be followed by a biopsy for histological confirmation of diagnosis. OCT magnifies the skin for a more detailed examination compared to standard techniques. Using near-infrared light, tissue can be viewed on a microscale in real time [1]. Although the use of OCT is more prevalent, its effectiveness in diagnosing skin cancer and its overall accuracy are insufficiently characterized [2].

A 2018 Cochrane review, "Optical Coherence Tomography for Diagnosing Skin Cancer in Adults," provides an in-depth review of the accuracy of OCT for detecting skin abnormalities. Data from five test accuracy studies were obtained, permitting comparison of the index test to a reference standard. The diagnostic accuracy of OCT was assessed for melanoma (n=2) and keratinocyte carcinomas (n=3). There were insufficient data to determine the diagnostic accuracy of OCT for melanoma or cutaneous squamous cell carcinoma. In a sample of 346 lesions (n=2 studies), the sensitivity and specificity of OCT for detecting basal cell carcinoma (BCC) was potentially superior versus visual assessment and dermoscopic exam—however, given a limited sample size and the high prior probability of BCC, results must be interpreted cautiously. Applied to a hypothetical population (n=1000 people), OCT had better outcomes than

RenderX

visual and dermoscopic exams, correctly identifying 53 more BCC lesions while reducing the incidence of false positives and unnecessary excisions by 87 [2].

The high sensitivity and specificity of OCT for BCC diagnosis are noted in subsequent reviews and expert consensus [3,4]. An increasing emphasis on aesthetically mindful outcomes highlights the importance of noninvasive modalities like OCT, with minimally invasive treatment options such as Mohs surgery increasing over 300% in a 15-year span [5]. For BCC, the use of OCT could potentially reduce the need for biopsy and histological confirmation by as much as 33% [3]. Despite its promise for BCC diagnosis, OCT accuracy may not be generalized to all suspect lesions. In cases of nonmelanoma lesions where the differential excludes BCC, OCT may result in overdiagnosis and, in some reports, a high incidence of false negatives [4]. Applying OCT to other skin lesions may, therefore, result in negative consequences (eg, misdiagnosis, repeat testing); with insufficient data regarding its accuracy [2], this raises the question of whether the benefit of noninvasive testing outweighs the risks.

The insufficient number of studies available for inclusion, study heterogeneity, and restricted study populations limit the conclusions that may be drawn regarding the diagnostic utility of OCT [2]. Included studies exhibited poor reporting, prohibiting a risk of bias assessment; additionally, study results may not be applicable to standard clinical practice [2]. Future studies should be of high methodological quality, clarify

## JMIR DERMATOLOGY

recruitment methods, and incorporate a blinded reference standard for results comparison [2]. Considering rapid technological advancements in OCT [1], well-conducted studies

may enable its broader application to clinical practice in the near future.

# Acknowledgments

The authors gratefully acknowledge Dr Jac Dinnes for providing expert insight and reviewing this manuscript.

## **Conflicts of Interest**

RPD is the editor in chief of JMIR Dermatology, a joint coordinating editor of Cochrane Skin, a dermatology section editor for UpToDate, and a social media editor for the Journal of the American Academy of Dermatology. He is a coordinating editor representative on Cochrane Council. TS is an editorial board member-at-large for JMIR Dermatology. RPD receives editorial stipends (JMIR Dermatology, Journal of Investigative Dermatology), royalties (UpToDate), and expense reimbursement (Cochrane Skin). TS receives fellowship funding from Pfizer (grant 25B1519; principal investigator: Stanca Birlea) and the National Institutes of Health (grant 2T32AR00741136A1; principal investigator Dennis Roop).

## References

- Zysk AM, Nguyen FT, Oldenburg AL, Marks DL, Boppart SA. Optical coherence tomography: a review of clinical development from bench to bedside. J Biomed Opt 2007;12(5):051403 [FREE Full text] [doi: 10.1117/1.2793736] [Medline: 17994864]
- Ferrante di Ruffano L, Dinnes J, Deeks JJ, Chuchu N, Bayliss SE, Davenport C, Cochrane Skin Cancer Diagnostic Test Accuracy Group. Optical coherence tomography for diagnosing skin cancer in adults. Cochrane Database Syst Rev 2018 Dec 04;12(12):CD013189. [doi: 10.1002/14651858.CD013189] [Medline: <u>30521690</u>]
- 3. Dorrell DN, Strowd LC. Skin cancer detection technology. Dermatol Clin 2019 Oct;37(4):527-536. [doi: 10.1016/j.det.2019.05.010] [Medline: <u>31466592</u>]
- 4. Pathania YS, Apalla Z, Salerni G, Patil A, Grabbe S, Goldust M. Non-invasive diagnostic techniques in pigmentary skin disorders and skin cancer. J Cosmet Dermatol 2022 Feb;21(2):444-450. [doi: 10.1111/jocd.14547] [Medline: 34724325]
- Wang DM, Morgan FC, Besaw RJ, Schmults CD. An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015. J Am Acad Dermatol 2018 Jan;78(1):47-53. [doi: 10.1016/j.jaad.2017.09.031] [Medline: 28947293]

## Abbreviations

**BCC:** basal cell carcinoma **OCT:** optical coherence tomography

Edited by R Alhusayen; submitted 22.07.22; peer-reviewed by D Di Stasio, J Makin, H Mohammed, C Heckman; comments to author 08.02.23; revised version received 22.02.23; accepted 01.03.23; published 13.03.23

<u>Please cite as:</u> Burnette C, Sivesind TE, Dellavalle R From the Cochrane Library: Optical Coherence Tomography for Diagnosing Skin Cancer in Adults JMIR Dermatol 2023;6:e41355 URL: https://derma.jmir.org/2023/1/e41355 doi: <u>10.2196/41355</u> PMID:

©Colin Burnette, Torunn E Sivesind, Robert Dellavalle. Originally published in JMIR Dermatology (http://derma.jmir.org), 13.03.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on http://derma.jmir.org, as well as this copyright and license information must be included.

RenderX